Research ArticleCancer
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
- Bing Z. Carter1,*,
- Po Yee Mak1,†,
- Hong Mu1,†,
- Hongsheng Zhou1,
- Duncan H. Mak1,
- Wendy Schober1,
- Joel D. Leverson2,
- Bin Zhang3,
- Ravi Bhatia4,
- Xuelin Huang5,
- Jorge Cortes6,
- Hagop Kantarjian6,
- Marina Konopleva1 and
- Michael Andreeff1,*
- 1Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- 2Department of Oncology Development, AbbVie Inc., North Chicago, IL 60064, USA.
- 3Division of Hematopoietic Stem Cell and Leukemia Research, Beckman Research Institute, City of Hope Cancer Center, Duarte, CA 91010, USA.
- 4Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
- 5Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- 6Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- ↵*Corresponding author. Email: bicarter{at}mdanderson.org (B.Z.C.); mandreef{at}mdanderson.org (M.A.)
↵† These authors contributed equally to this work.
See allHide authors and affiliations
Science Translational Medicine 07 Sep 2016:
Vol. 8, Issue 355, pp. 355ra117
DOI: 10.1126/scitranslmed.aag1180
Vol. 8, Issue 355, pp. 355ra117
DOI: 10.1126/scitranslmed.aag1180
Bing Z. Carter
1Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Po Yee Mak
1Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hong Mu
1Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hongsheng Zhou
1Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Duncan H. Mak
1Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Wendy Schober
1Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Joel D. Leverson
2Department of Oncology Development, AbbVie Inc., North Chicago, IL 60064, USA.
Bin Zhang
3Division of Hematopoietic Stem Cell and Leukemia Research, Beckman Research Institute, City of Hope Cancer Center, Duarte, CA 91010, USA.
Ravi Bhatia
4Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Xuelin Huang
5Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jorge Cortes
6Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hagop Kantarjian
6Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Marina Konopleva
1Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Michael Andreeff
1Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
